Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

111

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

September 12, 2018

Conditions

Breast NeoplasmsmTor Protein

Interventions

DRUG

Tamoxifen

20mg daily (1 cap) until unbearable toxicity or progression

DRUG

Everolimus

10mg daily (2 caps of 5mg) until unbearable toxicity or progression

Trial Locations (1)

Hopital Hotel Dieu, Paris